Top Page
Immuron Limited
(Sydney:IMC)
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Immuron Limited Business Overview & Revenue Model
Immuron Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.93M | 7.29M | 4.90M | 1.80M | 765.19K | 145.78K |
| Gross Profit | 5.82M | 4.77M | 3.34M | 1.31M | 523.50K | 94.70K |
| EBITDA | -6.70M | -5.31M | -6.19M | -3.80M | -3.08M | -8.33M |
| Net Income | -6.58M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
Balance Sheet | ||||||
| Total Assets | 10.13M | 10.13M | 15.55M | 21.99M | 24.86M | 27.05M |
| Cash, Cash Equivalents and Short-Term Investments | 5.87M | 5.87M | 11.66M | 18.99M | 22.11M | 25.05M |
| Total Debt | 117.13K | 117.13K | 173.50K | 189.09K | 209.79K | 20.50K |
| Total Liabilities | 2.06M | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M |
| Stockholders Equity | 8.07M | 8.07M | 12.71M | 19.62M | 23.18M | 25.90M |
Cash Flow | ||||||
| Free Cash Flow | -7.21M | -6.14M | -5.56M | -2.50M | -3.14M | -4.09M |
| Operating Cash Flow | -7.21M | -6.14M | -5.56M | -2.49M | -3.13M | -4.08M |
| Investing Cash Flow | -4.46M | -2.90M | 327.56K | -2.74M | 11.74K | 2.57K |
| Financing Cash Flow | 323.86K | 199.75K | 829.00 | -35.02K | -36.26K | 26.49M |
Immuron Limited Technical Analysis
Immuron Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$53.21M | -11.90 | -16.65% | ― | ― | -672.73% | |
46 Neutral | AU$25.72M | -5.09 | -157.93% | ― | ― | -36.89% | |
44 Neutral | AU$13.07M | -1.73 | -49.96% | ― | 48.63% | 25.66% | |
44 Neutral | AU$36.73M | -9.09 | -143.71% | ― | 306.88% | ― | |
40 Underperform | AU$4.39M | -1.35 | -205.70% | ― | ― | 1.03% | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Immuron Limited Corporate Events
Immuron Limited has announced that its Chief Executive Officer, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on 22 January 2026, with the session to be made available via live webcast and archived online for later viewing. The appearance is expected to enhance the company’s visibility among growth-focused investors and stakeholders by showcasing its targeted antibody platform and portfolio of gastrointestinal and infectious disease-focused products, potentially strengthening its positioning in the global biopharmaceutical and travel health markets.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has called an extraordinary general meeting of shareholders for 12 February 2026 in Melbourne to seek approval for the ratification of two substantial prior share issuances. Shareholders will be asked to ratify the issue of 28,278,923 shares under ASX Listing Rule 7.1 and a further 26,821,997 shares under Listing Rule 7.1A, moves that effectively regularize past capital-raising activities and restore the company’s capacity to issue additional equity in the future. The resolutions, if approved, will support Immuron’s flexibility in accessing capital markets going forward, which is significant for its ongoing funding needs and could influence future dilution, governance considerations, and the company’s ability to finance its development and commercial objectives.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the issuance of 314,843 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This move is part of the company’s ongoing efforts to maintain transparency and adhere to regulatory requirements, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the application for quotation of 314,843 ordinary fully paid securities on the Australian Securities Exchange (ASX), with an issue date of December 16, 2025. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase its capital base, which could have implications for its operational capabilities and stakeholder interests.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has issued 1,142,909 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This issuance indicates the company’s adherence to regulatory requirements and suggests a strategic move to potentially enhance its financial position and operational capabilities.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the issuance of 1,142,909 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX) as of December 15, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase liquidity, reflecting its ongoing efforts to strengthen its financial position and operational capabilities.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the issuance of 1,874,964 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This strategic move is part of the company’s efforts to strengthen its financial position, potentially impacting its operational capabilities and market presence.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced that the Uniformed Services University released topline results from a clinical trial evaluating a third-party manufactured product containing ETEC hyperimmune bovine colostrum. The trial did not achieve statistical significance for its primary endpoint, and the product was not administered according to Travelan® directions. As a result, Immuron does not consider these results reflective of Travelan®’s performance. The company plans to propose its established three-times-daily dosing schedule at an upcoming FDA meeting. Immuron continues to collaborate with military research institutions on vaccines and is advancing discussions for testing Travelan® against other E. coli strains.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced the quotation of 45,472,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This move is expected to enhance the company’s market presence and provide additional capital for its ongoing projects, potentially impacting its operational capabilities and stakeholder interests positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced a proposed issue of 45,472,000 ordinary fully paid securities, with the issue date set for December 5, 2025. This move is part of a placement or other type of issue, which could potentially impact the company’s market positioning by increasing its capital base and providing additional resources for its operations.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced a change in its share registry management services, transitioning from Automic Group to Boardroom Pty Limited effective December 8, 2025. This strategic move is expected to streamline the company’s administrative processes, potentially enhancing operational efficiency and stakeholder relations.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced a new research agreement funded by the U.S. Department of Defense to develop two oral therapeutics targeting Campylobacter and Shigella, in collaboration with the Naval Medical Research Command and the Walter Reed Army Institute of Research. This initiative aims to produce hyper-immune bovine colostrum products for the U.S. military, addressing the significant global burden of diarrheal diseases, which impact military readiness and global health. Additionally, Immuron is preparing to release results from a clinical trial on the effectiveness of its ETEC hyperimmune bovine colostrum in maintaining gut health during deployment and travel, highlighting its ongoing efforts to combat antibiotic-resistant enteric pathogens.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced a change in the director’s interest notice, specifically regarding Ravi Savarirayan. On November 18, 2025, Ravi Savarirayan acquired an additional 1,000,000 unlisted options, increasing his direct holdings to 2,000,000 options. This change was approved by shareholders during the company’s Annual General Meeting on November 11, 2025, indicating shareholder support for the director’s increased stake.
Immuron Limited announced a change in the director’s interest, with Paul Brennan acquiring 1,000,000 unlisted options, increasing his direct holdings to 2,000,000 options. This change was approved by shareholders during the company’s Annual General Meeting, potentially strengthening the alignment of the director’s interests with the company’s strategic goals.
Immuron Limited announced a change in the director’s interest, with Dr. Jeannette Joughin acquiring an additional 1,000,000 unlisted options, bringing her total to 2,000,000. This change was approved by shareholders at the company’s Annual General Meeting, indicating a strategic alignment with the company’s growth objectives and potentially impacting its market positioning.
Immuron Limited announced a change in the director’s interest, with Daniel Pollock acquiring an additional 1,000,000 unlisted options, as approved by shareholders at the company’s Annual General Meeting. This change reflects the company’s ongoing efforts to align its leadership’s interests with its strategic goals, potentially impacting its market positioning and stakeholder confidence.
Immuron Limited has announced the issuance of 4,000,000 unquoted securities under an employee incentive scheme, which are subject to transfer restrictions until the end of the restriction period. This move could potentially enhance employee engagement and align interests with company performance, impacting the company’s operational dynamics and stakeholder relations.
Immuron Limited announced that all resolutions proposed at its 2025 Annual General Meeting were successfully passed by shareholders. This outcome supports the company’s strategic direction and may positively influence its operational and market positioning, reinforcing stakeholder confidence in its governance and future initiatives.
Immuron Limited’s CEO, Steve Lydeamore, addressed the company’s Annual General Meeting, highlighting the company’s ongoing focus on developing innovative treatments for infectious diseases. The announcement underscores Immuron’s commitment to leveraging its unique platform technology to enhance its market position and deliver value to stakeholders.
Immuron Limited has received FDA approval for its Investigational New Drug (IND) application for IMM-529, allowing the company to proceed with a Phase 2 clinical trial targeting Clostridioides difficile infection (CDI). The trial aims to evaluate the safety and efficacy of IMM-529 as an adjunctive therapy with standard care, potentially positioning it as an early treatment option for CDI, a significant healthcare-associated infection. The development of IMM-529 addresses the urgent need for new therapeutics to reduce antibiotic reliance, with projections indicating a potential annual revenue of $400 million if successful.
Immuron Limited has provided an update on its clinical trials for Travelan® and IMM-529. The company’s IND application for IMM-529, aimed at preventing or treating Clostridioides difficile infection, is under review by the FDA, with minor updates submitted following a request for additional information. Additionally, the release of topline data from the Travelan® P2TD study has been delayed due to a U.S. government shutdown, impacting the company’s dosing strategy for an upcoming FDA meeting. The outcomes of these trials are crucial for Immuron’s strategic planning and could influence its market positioning and stakeholder interests.
Immuron Limited announced the cessation of 500,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of October 26, 2025. This announcement may impact the company’s capital structure but does not indicate immediate changes in its operational strategies or market positioning.
Immuron Limited has launched PROIBS®, a new product aimed at treating symptoms of Irritable Bowel Syndrome (IBS) in the Australian market. This launch is strategically timed for the festive season when IBS symptoms are more prevalent. PROIBS® is a certified medical device containing AVH200®, derived from Aloe barbadensis, and is designed for long-term use without known medication interactions. The product has shown promising results in a usability study, with a high percentage of users reporting improvements. This addition to Immuron’s product line, which includes the successful Travelan® brand, is expected to strengthen its position in the digestive health market, which is projected to grow in Australia.
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Emerging Growth Conference, highlighting the company’s advancements in biopharmaceuticals. This presentation underscores Immuron’s commitment to leveraging its proprietary technology to address infectious diseases, potentially enhancing its market position and offering significant benefits to stakeholders.
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the AusBiotech Invest 2025 conference, highlighting the company’s advancements in biopharmaceuticals. This presentation underscores Immuron’s commitment to leveraging its proprietary technology to address infectious diseases, potentially enhancing its market position and offering significant implications for stakeholders, particularly in the areas of travelers’ health and gastrointestinal treatments.
Immuron Limited has announced the issuance of 1,133,840 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company confirms compliance with relevant provisions of the Corporations Act and states there is no excluded information requiring disclosure, indicating a transparent operational stance.
Immuron Limited has announced the quotation of 1,133,840 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 20, 2025. This move is part of previously announced transactions and could potentially enhance the company’s market presence and liquidity, impacting its operations and positioning within the biotechnology sector.